Díaz-Cerezo Silvia, Artime Esther, Redondo-Antón Jennifer, Duque Natalia, Spaepen Erik, Mangas Cruz Miguel Ángel, Arnas-Leon Claudia, Olveira Gabriel, Rodríguez Irene Rodríguez, Julián Alagarda María Teresa, Valdés Nuria, Merchante Agustín Ángel, Masmiquel Lluís, Rubio-de Santos Miriam
Medical Department. Eli Lilly and Company, Alcobendas, Madrid, Spain.
HaaPACS GmbH, Schriesheim, Germany.
Patient Prefer Adherence. 2025 May 1;19:1231-1244. doi: 10.2147/PPA.S509483. eCollection 2025.
This study compared patient-reported compliance with package leaflet administration instructions of two glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for the treatment of type 2 diabetes (T2D): weekly injectable dulaglutide and daily oral semaglutide.
This was an observational cross-sectional study conducted in Endocrinology Units in Spain. Patients with T2D receiving weekly injectable dulaglutide or daily oral semaglutide at study enrolment who had initiated treatment 3-12 months before were consecutively recruited during routine visits. Clinical data were extracted from the participants´ medical records. An ad-hoc questionnaire asked how often all and each of the administration instructions specific to each treatment were being followed (eg, timing, steps of intake). Compliance in both groups was calculated using relative and absolute frequencies and matching using the FMA model. The relationship between compliance and sociodemographic/clinical variables was assessed using bivariate analyses. Logistic regression analyses were performed to identify predictors of compliance.
A total of 95 participants treated with weekly injectable dulaglutide and 135 participants treated with daily oral semaglutide were evaluated. More participants treated with weekly injectable dulaglutide (96.8%) than participants treated with daily oral semaglutide (90.4%) were compliant with all package leaflet administration instructions. After adjusting for potential between-group imbalances, higher compliance in the weekly injectable dulaglutide group compared with the daily oral semaglutide group was observed (odds ratio=3.2, 95% confidence interval 1.4-21.3).
Compliance with package leaflet administration instructions was significantly higher in patients with T2D receiving weekly injectable dulaglutide compared to those receiving daily oral semaglutide. This type of real-world compliance data can inform strategies to improve patient education and adherence, and physician prescribing practices, with the goal of ultimately leading to better clinical outcomes and quality of life.
本研究比较了患者报告的两种用于治疗2型糖尿病（T2D）的胰高血糖素样肽1受体激动剂（GLP-1 RAs）的药品说明书给药说明的依从性：每周注射一次的度拉糖肽和每日口服的司美格鲁肽。
这是一项在西班牙内分泌科进行的观察性横断面研究。在研究入组时接受每周注射一次度拉糖肽或每日口服司美格鲁肽且在3至12个月前开始治疗的T2D患者在常规就诊期间被连续招募。临床数据从参与者的病历中提取。一份专门设计的问卷询问了每种治疗特定的所有给药说明以及每条给药说明的遵循频率（例如，时间安排、服用步骤）。两组的依从性通过相对频率和绝对频率计算，并使用FMA模型进行匹配。使用双变量分析评估依从性与社会人口统计学/临床变量之间的关系。进行逻辑回归分析以确定依从性的预测因素。
共评估了95名接受每周注射一次度拉糖肽治疗的参与者和135名接受每日口服司美格鲁肽治疗的参与者。与接受每日口服司美格鲁肽治疗的参与者（90.4%）相比，接受每周注射一次度拉糖肽治疗的参与者中遵循所有药品说明书给药说明的比例更高（96.8%）。在对潜在的组间不平衡进行调整后，观察到每周注射一次度拉糖肽组的依从性高于每日口服司美格鲁肽组（优势比=3.2，95%置信区间1.4 - 21.3）。
与接受每日口服司美格鲁肽的T2D患者相比，接受每周注射一次度拉糖肽的患者对药品说明书给药说明的依从性显著更高。这类真实世界的依从性数据可为改善患者教育和依从性以及医生处方实践的策略提供信息，最终目标是实现更好的临床结局和生活质量。
